What ejection fraction (EF) cutoff defines risk for non‑cardiac surgery?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

EF Cutoff for Risk in Non-Cardiac Surgery

An ejection fraction below 30% defines markedly increased perioperative risk in non-cardiac surgery, with mortality risk more than doubling compared to patients without heart failure 1.

Risk Stratification by EF Thresholds

The 2026 AHA/ACC guideline provides the most definitive contemporary data on EF-based risk stratification 1:

  • LVEF <30%: Adjusted odds ratio of 2.35 for 90-day mortality (crude mortality 8.34%)
  • LVEF 30-39%: Adjusted odds ratio of 1.85 for 90-day mortality (crude mortality 6.58%)
  • LVEF 40-49%: Adjusted odds ratio of 1.53 for 90-day mortality (crude mortality 5.11%)
  • LVEF ≥50%: Adjusted odds ratio of 1.51 for 90-day mortality (crude mortality 4.88%)

This data from 609,735 patients undergoing non-cardiac surgery demonstrates a clear stepwise increase in mortality as EF declines, with the most dramatic risk elevation occurring below 30%.

Practical Clinical Thresholds

The 30% threshold represents the critical cutoff where perioperative risk becomes substantially elevated. Older data from carotid surgery identified 35% as a threshold where perioperative cardiac complications occurred in 43% of cases versus 9% in those with higher EF 2. However, the more recent and larger guideline dataset supports 30% as the contemporary standard 1.

A 2021 study identified 58% as an optimal cutoff for predicting perioperative adverse cardiovascular events (sensitivity 80%, specificity 61%) 3, but this represents a statistical optimization rather than a clinically actionable threshold for high-risk designation.

Critical Context: EF Alone Is Insufficient

The presence of active heart failure symptoms matters more than the EF number itself. Patients with compensated heart failure and low EF may have lower risk than those with HFpEF and clinical decompensation 1. The guideline emphasizes that patients with active HF symptoms or signs are at higher risk than those with compensated HF or history of HF alone 1.

For patients with advanced heart failure (NYHA class III-IV) who are clinically decompensated or hemodynamically unstable, postpone elective surgery regardless of the specific EF value and obtain cardiology consultation 1.

Perioperative Management Based on EF

Continue guideline-directed medical therapy (GDMT) through the perioperative period for all patients with heart failure, with one critical exception 1:

  • Withhold SGLT2 inhibitors for 3-4 days before surgery (canagliflozin, dapagliflozin, empagliflozin ≥3 days; ertugliflozin ≥4 days) to prevent perioperative metabolic acidosis 1
  • Continue all other HF medications (ACE inhibitors, ARBs, beta-blockers, mineralocorticoid receptor antagonists) unless specifically contraindicated 1

Interruption of GDMT without specific indication increases mortality 1.

Common Pitfalls

  • Do not use EF as the sole risk determinant. Functional capacity, volume status, and clinical stability are more robust predictors of short-term perioperative risk 4
  • Do not assume preserved EF equals low risk. HFpEF with congestion or right ventricular dysfunction may carry higher risk than compensated HFrEF 4
  • Do not forget to assess for diastolic dysfunction, venous congestion, and right ventricular function beyond the EF number 4

Related Questions

In a 79‑year‑old woman with heart failure with preserved ejection fraction (EF ≈ 58 %), uncontrolled hypertension (home blood pressure ~164/108 mmHg), rising NT‑proBNP, mild dyslipidaemia, hyperuricaemia, asymptomatic pyuria, and current therapy including low‑dose rosuvastatin, telmisartan 40 mg twice daily, carvedilol, Doreta SR (amlodipine/olmesartan) 75/650 mg once daily, and zolpidem, how should her treatment be optimized?
In a 61-year-old man with hypertension, a 30‑pack‑year smoking history, and 2‑day exertional dyspnea with only basal crackles, which laboratory test is most specific and helpful for diagnosing heart failure?
What is the recommended guideline‑directed medical therapy for a patient with mildly reduced left ventricular ejection fraction (40‑45 %) and the following echocardiographic findings: moderate concentric left ventricular hypertrophy, inferior and inferolateral wall hypokinesis, Grade I diastolic dysfunction, severely dilated left atrium, calcific aortic valve without stenosis or regurgitation, mild mitral stenosis and regurgitation, and trace tricuspid regurgitation?
What are the ACC/AHA guideline recommendations for perioperative cardiovascular evaluation, risk stratification, and medication management in adult patients undergoing non‑cardiac surgery?
Should a 74‑year‑old woman with hypertension, hypothyroidism, heart‑failure with preserved ejection fraction, paroxysmal atrial fibrillation, hyperlipidemia and a rapid rise in serum creatinine from 1.9 mg/dL to 2.75 mg/dL (estimated GFR decreasing from ~27 to ~17 mL/min) be taken to the emergency department?
Is there a validated clinical prediction score for suspected meningitis?
Which laboratory tests should be ordered to evaluate bleeding and coagulation abnormalities?
In a patient with progressive hypersensitivity pneumonitis who has a split, ulcerated rash in the intergluteal cleft (perianal area), could the rash be related to the lung disease?
What is the appropriate evaluation and management for a patient with a markedly elevated blood urea nitrogen (BUN)?
What is the most common presenting symptom in children with childhood-onset schizophrenia?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.